The Michael J. Fox Foundation-led project aims to lead researchers to new insights about biomarkers indicating Parkinson's disease progression.
NanoView will develop custom antibody-based assays on its ExoView platform to identify EVs containing biomarkers potentially linked to the neurological disorders.
A SUNY Upstate team identified potential PD biomarkers in patients' oral microbiomes, which may lead to a saliva-based assay for early-stage disease.
The group will start a pilot study at Columbia University next week to sequence genes from 600 Parkinson's disease patients before expanding to a larger cohort.
Fulgent will use its Parkinson's disease NGS panel to target seven genes linked to the condition and generate curated reports for doctors and researchers.
The study aims to identify individuals with mutations in Parkinson's disease-associated genes for further analysis.
The firm is developing and beta-testing a line of guide RNA libraries to support CRISPR-based targeted capture and sequencing approaches.
The firm is seeking damages and various injunctions, citing 11 different counts of fraud, breach of contract, tortious interference, and unfair competition.
The funding is being provided to a number of early-career investigators and collaborative research groups using genomics and other technologies.
The researchers reported that targeting HDAC4 in the patient-derived neurons appeared to correct the expression of genes that differed in the disease state.
Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.
Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.